Acadia Pharmaceuticals announced that Health Canada has accepted its New Drug Submission, or NDS, for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals to present trofinetide findings in Rett syndrome at AAN
- Largest borrow rate increases among liquid names
- Acadia Pharmaceuticals price target lowered to $25 from $29 at JPMorgan
- Biotech Alert: Searches spiking for these stocks today
- Acadia Pharmaceuticals price target lowered to $30 from $40 at Morgan Stanley
